Assessing the safety, impact and effectiveness of RTS,S/AS01(E) malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up

BACKGROUND: Following a 30-year development process, RTS,S/AS01(E) (GSK, Belgium) is the first malaria vaccine to reach Phase IV assessments. The World Health Organization-commissioned Malaria Vaccine Implementation Programme (MVIP) is coordinating the delivery of RTS,S/AS01(E) through routine natio...

Descripción completa

Detalles Bibliográficos
Autores principales: Praet, Nicolas, Asante, Kwaku Poku, Bozonnat, Marie-Cecile, Akité, Elaine Jacqueline, Ansah, Patrick Odum, Baril, Laurence, Boahen, Owusu, Mendoza, Yolanda Guerra, Haine, Valerie, Kariuki, Simon, Lamy, Mathieu, Maleta, Kenneth, Mungwira, Randy, Ndeketa, Latif, Oduro, Abraham, Ogutu, Bernhards, Olewe, Fredrick, Oneko, Martina, Orsini, Mattéa, Roman, Francois, Bahmanyar, Edith Roset, Rosillon, Dominique, Schuerman, Lode, Sing’oei, Valentine, Terlouw, Dianne J., Wéry, Stéphanie, Otieno, Walter, Pirçon, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036501/
https://www.ncbi.nlm.nih.gov/pubmed/35468801
http://dx.doi.org/10.1186/s12936-022-04144-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036501/
https://www.ncbi.nlm.nih.gov/pubmed/35468801
http://dx.doi.org/10.1186/s12936-022-04144-3

Ejemplares similares